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CS7.2 Hepatitis B virus: Genotypic and virological
resistance
P.-J. Chen*. National Taiwan University and Hospital,
Taipei, Taiwan
Current nucleotide or nucleoside analogs have been
commonly applied to treat chronic hepatitis B patients.
These drugs effectively block de novo HBV DNA synthesis
and almost suppress HBV replication. It always achieves
a depletion of HBV virions from the blood stream of
the patients. However, it could not eradicate HBV DNA,
especially the ccc DNA, in the hepatocytes already infected
by HBV. The intrahepatic HBV cccDNA continue active
transcription and reverse transcription, an error-prone
process to generate large population of HBV variants. A tiny
proportion of these HBV variants may acquire the ability to
escape the suppression of nucleot(s)ide analogs, because of
their genetic changes. These genetic changes may confer
the ability of variant HBV able to start replication, even
in the presence of anti-viral NAs. Despite of this new
capacity, such variants usually replicate poorly, unless they
acquire new mutations which compensate the replication
activity (so-called compensatory mutations, or secondary
mutations). Therefore it is important to distinguish between
genotypic resistance to vriological resistance towards anti-
viral NAs. The sequences variants in the HBV genomes render
viruses able to replicate (even minimally) in the anti-viral
NAs are named genotypic resistance. However, many of
these mutants are not potent enough to support active HBV
variant replication, so few HBV are released and detected.
Until there are other new genotypic mutations take place
and make the replication level sufﬁcient high, then the HBV
variants become prominent in the circulation and result
in the virological resistance. New detection and evaluation
platforms, such as deep sequencing or new animal models
will be discussed for their application for this important
issue.
CS7.3 cccDNA function and HBV replication
M. Levrero*, L. Belloni, F. Guerrieri, N. Pediconi. Dept.
of Internal Medicine DMISM and the LifeNanoscience
Laboratory, Sapienza University of Rome, Rome, Italy
HBV cccDNA, the template for transcription of all viral
mRNAs, accumulates in the nucleus of infected cells as a
stable episome organized into minichromosomes by histones
and non-histone viral and cellular proteins (Levrero et
al., J. Hepatol 51, 581, 2009). The accumulation and the
maintenance of the cccDNA pool is ensured in infected
hepatocytes by newly synthesized nucleocapsids which
are not enveloped and secreted into the blood, but are
transported into the nucleus. In quiescent cells the cccDNA
is very stable and can persist throughout the life span of
the hepatocytes without affecting its viability. A reduction
of the cccDNA pool in the infected liver can be achieved
either by cell death or through cccDNA dilution during cell
division. Thus, liver cell death and regeneration that occur
in chronically infected livers may be instrumental not only
to eliminate infected cells but also to induce hepatocyte
proliferation which, in turn, may favour cccDNA loss. On
the other hand, very low levels of cccDNA can persist
indeﬁnitely, possibly explaining lifelong immune responses
to HBV despite clinical resolution of HBV infection. As HBV
polymerase inhibitors do not directly affect the cccDNA,
a decrease in cccDNA levels in patients treated with
nucleot(s)ide analogs is supposed to derive from the lack
of sufﬁcient recycling of viral nucleocapsids to the nucleus,
due to the strong inhibition of viral DNA synthesis in the
cytoplasm, and less incoming viruses from the blood. Under
this scenario, cccDNA depletion requires many years of
nucleos(t)ide drug administration and it is expected to lead
to the selection of resistant variants. Only a simultaneous
treatment with antiviral agents acting through different
mechanisms or capable of affecting cccDNA stability will
hopefully lead to the eradicating of the cccDNA from the
liver and achieve clearance of HBV infection.
We have developed a chromatin immuno-precipitation
(ChIP)-based quantitative technique to study the
recruitment in vivo of cellular and viral proteins onto the
HBV minichromosome (Pollicino et al., Gastroenterology
130, 823, 2006). The HBV cccDNA ChIP assay combines a ChIP
step with a sensitive and speciﬁc real-time PCR protocol
for cccDNA quantiﬁcation. Using an anti-acetylated-H3 or
-H4 cccDNA ChIP assay we found that HBV replication
is regulated, both in HBV replicating Huh7 cells and
in the liver of HBV chronically infected patients by
the acetylation status of H3/H4 histones bound to the
viral cccDNA. Moreover, cellular histone acetyltransferases
CBP, p300 and PCAF/GCN5 and the histone deacetylases
HDAC1 and hSirt1 are all recruited in vivo onto the
cccDNA (Levrero et al., J. Hepatol 51, 581, 2009). We
also found that the HBx regulatory protein produced
in HBV replicating cells is recruited onto the cccDNA
minichromosome. The HBx mutant cccDNA is impaired
in its replication, transcribes signiﬁcantly less pgRNA,
displays a severe impairment in p300 recruitment, an
increased recruitment of the histone deacetylases hSirt1
and HDAC1 and hypoacetylation of cccDNA-bound histones.
These results identify a novel epigenetic mechanism (i.e. to
prevent cccDNA deacetylation) by which HBx controls HBV
replication (belloni et al., PNAS USA 106, 19975, 2009). We
also found that in HBV replicating cells alpha-IFN treatment
leads to a rapid and strong decrease in both cccDNA-bound
histone acetylation and pgRNA transcription from cccDNA
that are paralleled by the recruitment of the transcriptional
corepressors HDAC1, hSirt1, YY1 and the Polycomb proten
Ezh2 (Belloni et al., submitted to J Clin Invest).
These observations provide a molecular mechanism for
alpha-IFN repression of HBV transcription. Altogether our
results support the existence of a complex network of
epigenetic events that inﬂuence cccDNA function and HBV
replication.
CS7.4 Tools for the assessment of HBV resistance in
clinical practice
V.C.S. Wong*. Department of Medicine and Therapeutics,
The Chinese University of Hong Kong, Hong Kong S.A.R.
Chronic hepatitis B is the leading cause of cirrhosis and
hepatocellular carcinoma in Asia. Antiviral therapy against
hepatitis B virus (HBV) has been shown to reduce the
risk of complications, particularly in patients who have
sustained or maintained response to treatment. However,
long-term antiviral therapy is limited by the emergence of
drug-resistant mutants. Drug resistance results in increase
in viral load, hepatitis ﬂares, histological deterioration and
even liver decompensation. While newer antiviral drugs such
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as entecavir and tenofovir have low risk of resistance, for
historical reasons many patients in Asia have been exposed
to drugs with low genetic barrier to resistance.
To detect drug resistance, vigilant monitoring of HBV DNA
level is essential. Virological breakthrough is deﬁned as a
rise of HBV DNA level by 10-fold during antiviral therapy
and is indicative of drug resistance. When virological
breakthrough develops, salvage antiviral therapy with a
drug without cross-resistance should be initiated as soon
as possible to ensure treatment success. Nevertheless, in
some cases the selection of salvage therapy is not always
straightforward. For example, while adefovir dipivoxil or
tenofovir is commonly used to treat lamivudine resistance,
the mutant rtA181T/V confers resistance or reduced
sensitivity to all three agents but remains sensitive to
entecavir.
Drug resistance testing is used to identify the culprit mutant
and aids clinicians in choosing the optimal antiviral agent. In
a recent survey, drug resistance testing altered management
in over half of the cases. Two types of commercial assays
are available direct sequencing (TRUGENE HBV, Siemens
Health Care Diagnostic Solutions, and Afﬁgene HBV DE/3TC
Assay, Sangtec Molecular Diagnostics AB) and reverse
hybridization (INNO-LiPA DR Version 2.0, Innogenetics).
Direct sequencing of the polymerase gene has the advantage
of identifying both known and previously unreported
mutations. However, the test may be falsely negative
if the mutants constitute less than 20% of the whole
population. Besides, the detection of new mutations is
common and may not necessarily represent drug resistance.
In vitro phenotypic analysis is required to conﬁrm decreased
susceptibility to treatment.
In contrast, hybridization assays are more sensitive and
can detect mutants that constitute only 5% of the
whole population. Nevertheless, one major limitation of
hybridization assays is that only known mutations can be
detected. When new drug-resistant mutations are reported,
the test needs regular updating.
Mass spectroscopy represents an inexpensive and sensitive
method that may detect mutant population that represents
5% of the overall population. Ultradeep pyrosequencing is
another more sensitive technique. These new technologies
may overcome the limitations of existing assays and warrant
further validation.
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CS9.1 Screening of inﬂuenza
L.C. Jennings *. Canterbury Health Laboratories &
Department of Pathology, University of Otago,
Christchurch, New Zealand
Inﬂuenza continues to be a serious respiratory disease
globally and can become a major public health threat when
a novel virus with pandemic potential emerges. Classical
inﬂuenza presents with the sudden onset of fever followed
by systemic symptoms of muscle aches, malaise and a cough.
During an outbreak or epidemic, the accuracy of a clinician’s
diagnosis of inﬂuenza may have a PPV 79 87% and NPV
39 75%, while the PPV drops to 44% during periods of low
activity. Atypical presentations may also occur especially in
young children and the elderly, and the severity of symptoms
may vary from mild to severe. Further other viral infections
can present as inﬂuenza-like-illness. For these reasons, the
laboratory diagnosis of inﬂuenza may be required to assist
the antiviral treatment and management of patients in the
community and in hospital.
Many laboratories have focused on molecular diagnostics
(nucleic acid ampliﬁcation) following the avian inﬂuenza
outbreak in late 2003, then the H1N1 2009 pandemic,
because of this technologies high sensitivity, speciﬁcity,
potential for automation and staff safety considerations.
The perceived cost, minimum sample volume requirements
for batched testing using commercial platforms, and
the requirement for trained staff to ensure quality and
maintenance procedures are followed, has limited the
introduction of this technology into some laboratories.
Classical diagnostic methods involve the culture of
viable virus and the direct detection of viral antigen
by immunoﬂuoresence or immunocromatography assays.
Culture remains the gold standard, while the sensitivity
and speciﬁcity of antigen detection assays is limited by
the technology used, and their clinical usefulness (PPV and
NPV) is inﬂuenced by the level of inﬂuenza activity in the
community. An important consideration is the diagnostic
yield of inﬂuenza detection assays which can be affected
by a number of factors including the natural course of viral
shedding during an infection, the severity of disease, the
timing of a patient’s presentation for sampling and the type
and quality of respiratory sample obtained.
The role of the laboratory has changed following the recent
H1N1 pandemic. Public Health specialists now require
both positive and negative results in a timely manner to
assist the management of outbreaks. Clinicians also require
inﬂuenza A subtype and antiviral resistance information, all
of which requires the use of sensitive molecular assays.
The renewed focus on inﬂuenza surveillance has raised
the importance of other non-inﬂuenza respiratory viruses
and their detection. There are an increasing range of
commercial assays becoming available utilizing differing
molecular methods and primer designs. These automated
fully validated assays, with quality controlled reagents and
the auto-calling of results offer increased sensitivity and
rapid turnaround times for the detection of a wide range
of respiratory viruses. Few head-to-head comparisons are
available to allow assessment of their clinical usefulness.
CS9.2 The emergence of pandemic inﬂuenza viruses
G.J.D. Smith*. Program in Emerging Infectious Diseases,
Duke-NUS Graduate Medical School, Singapore
Inﬂuenza pandemics cause signiﬁcant human mortality. In
the 20th Century there were three recorded pandemics that
resulted in over 50 million human deaths. During March
and early April 2009, an H1N1 virus lineage previously
undetected in humans emerged in Mexico and the United
States. This novel virus was sufﬁciently antigenically
divergent from seasonal H1N1 that the human population
was immunologically naive. Subsequently this virus spread
rapidly via human-to-human transmission, developing into
the ﬁrst inﬂuenza pandemic in 40 years. Despite global
concern regarding pandemic inﬂuenza, the emergence
pathways of pandemic strains remained obscure. Here
the evolutionary history and inferred date of introduction
to humans of each of the genes for all four pandemic
inﬂuenza strains were calculated. Phylogenetic trees were
inferred using the neighbor-joining distance method, with
genetic distances calculated by maximum likelihood under
the Hasegawa Kishino Yano (HKY) model with gamma-
distributed rates among sites. Parameters of this model
were estimated using maximum likelihood on an initial
tree. Temporal phylogenies and rates of evolution were
inferred using a relaxed molecular clock model that allows
rates to vary among lineages within a Bayesian Markov
chain Monte Carlo (MCMC) framework. A model comprising
